<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4548">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047720</url>
  </required_header>
  <id_info>
    <org_study_id>1601620278</org_study_id>
    <nct_id>NCT03047720</nct_id>
  </id_info>
  <brief_title>Scheduled Awakenings for the Treatment of Nocturnal Enuresis</brief_title>
  <official_title>Scheduled Awakenings for the Treatment of Nocturnal Enuresis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a simple effectiveness trial to determine if the Lully Sleep Guardian has any
      effect on benign nocturnal enuresis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary monosymptomatic nocturnal enuresis (PMNE) is defined by the Diagnostic &amp; Statistical
      Manual of Mental Disorders (DSM- IV) as an involuntary voiding of urine during sleep, with a
      severity of at least twice a week, in children aged &gt;5 years in the absence of congenital or
      acquired defects of the central nervous system(1-3).

      PMNE affects 10-20% kids at 5 years old (1, 4, 5). It does resolve spontaneously so that 5%
      of 10 year olds and 1% of 15 year olds are still affected (2-4). Is more common in boys.
      While the disease its self is benign, and improves without intervention, it does pose a
      significant social and emotional burden on the child and their family. These include
      parental disapproval, sibling teasing, and inability to attend sleep overs with peers, all
      of which lead to families seeking treatment options (3, 4).

      Current treatments start with conservative management. This includes appropriate fluid
      intake, scheduled toileting during the day, avoidance of bladder irritants and constipation
      (4, 5). If these fail to improve symptoms or families are looking for a more active form of
      treatment, first line therapy is either a bed wetting alarms or desmopressin (1, 4, 5).

      The Lully Sleep Guardian was initially developed for use in night terrors. The device works
      by programing a vibrating disk that is placed under the child's bed to alter sleep patterns
      and prevent the onset of sleep terrors. The child is not woken up for the treatment of sleep
      terrors. The device has also been shown to anecdotally improve users' nocturnal enuresis.
      There have been no reports of safety concerns or hazards with the device (7, 8).

      The aim of this study is to determine the effectiveness of scheduled awakenings, with the
      Lully Sleep Guardian, in patients with PMNE, at reducing the frequency of bed-wetting.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of dry nights when using the scheduled awakening protocol with the Lully Sleep Guardian</measure>
    <time_frame>Daily reporting during the 6 week Therapeutic Phase</time_frame>
    <description>Family will be texted daily for this 6 weeks to document frequency of bed-wetting and severity while on therapeutic phase:
&quot;Did you use the Lully last night?&quot;
&quot;Did your child wet the bed last night?&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in number of voids per night when using the scheduled awakening protocol with the Lully Sleep Guardian</measure>
    <time_frame>Daily reporting during the 6 week Therapeutic Phase</time_frame>
    <description>Family will be texted daily for this 6 weeks to document frequency of bed-wetting and severity while on therapeutic phase:
&quot;Did you use the Lully last night?&quot;
&quot;Did your child wet the bed last night?&quot;
&quot;If yes, how wet was your child on scale of 1 - 5?&quot; (1: wet underwear; 2: wet underwear and damp pajamas; 3: soaked underwear, pajamas; 4: soaked pajamas, damp mattress - 5: soaked mattress)
&quot;Did your child wake up to go to the bathroom last night?&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quantity of wetness when bedwetting occurred while using the scheduled awakening protocol with the Lully</measure>
    <time_frame>Daily reporting during the 6 week Therapeutic Phase</time_frame>
    <description>Family will be texted daily for this 6 weeks to document frequency of bed-wetting and severity while on therapeutic phase:
&quot;Did you use the Lully last night?&quot;
&quot;Did your child wet the bed last night?&quot;
&quot;If yes, how wet was your child on scale of 1 - 5?&quot; (1: wet underwear; 2: wet underwear and damp pajamas; 3: soaked underwear, pajamas; 4: soaked pajamas, damp mattress - 5: soaked mattress)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QOL measures using the KIDS Screen Questionnaire comparing baseline, therapeutic phase, and follow up</measure>
    <time_frame>Baseline at initial enrollment, repeat before starting therapeutic phase (4 weeks study begins), and repeat at 8 week follow up (follow up 8 weeks after completion of 6 week therapeutic phase</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Nocturnal Enuresis</condition>
  <arm_group>
    <arm_group_label>1) Behavioral Modification Only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>behavioral modifications which includes: fluid restriction, managing constipation, and healthy voiding habits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2) Behavioral Modification and Lully</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>behavioral modifications in #1 with the addition of regular use of the Lully Sleep Guardian.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Behavioral Modification</intervention_name>
    <description>Will follow behavior modification guidelines presented in Wetting Accidents Voiding Education Booklet and Bedwetting Brief handout</description>
    <arm_group_label>1) Behavioral Modification Only</arm_group_label>
    <arm_group_label>2) Behavioral Modification and Lully</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lully</intervention_name>
    <description>6 weeks of scheduled awakening protocol using Lully Sleep Guardian: each night, a partial scheduled awakening will be performed with a vibrating mattress pad placed below the mattress. This will be used to reliably produce a partial awakening by titrating the device to a minimal awakening stimulus during the first night of use. If a partial awakening cannot be produced using the mattress pad, the parent will gently awaken the child</description>
    <arm_group_label>2) Behavioral Modification and Lully</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Benign nocturnal enuresis

          -  Age: 5 - 17

          -  Patient of Riley Pediatric Urology clinic

          -  Must have or have access to an Apple iPhone

        Exclusion Criteria:

          -  Diurnal Enuresis

          -  Constipation

          -  Neurogenic Bladder

          -  Any serious underlying cardiopulmonary problems

          -  Any bladder active medications

          -  Age: &lt; 5 years of age; &gt; 17 years of age

          -  Cerebral Palsy

          -  Mental disorders, mood disorders, or autism-spectrum disorder

          -  Epilepsy or seizure history

          -  Restless leg syndrome

          -  Use of benzodiazepine/clonidine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin M Whittam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Urology, Riley Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacy Keller, MSN</last_name>
    <phone>317-278-6127</phone>
    <email>stasulli@iupui.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Riley Hopspital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Keller, MSN</last_name>
      <phone>317-278-6127</phone>
      <email>stasulli@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin M Whittam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>1. National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Nocturnal Enuresis: The Management of Bedwetting in Children and Young People. London: Royal College of Physicians (UK) National Clinical Guideline Centre.; 2010.</citation>
  </reference>
  <reference>
    <citation>Ahmed AF, Amin MM, Ali MM, Shalaby EA. Efficacy of an enuresis alarm, desmopressin, and combination therapy in the treatment of saudi children with primary monosymptomatic nocturnal enuresis. Korean J Urol. 2013 Nov;54(11):783-90. doi: 10.4111/kju.2013.54.11.783. Epub 2013 Nov 6.</citation>
    <PMID>24255762</PMID>
  </reference>
  <reference>
    <citation>Glazener CM, Evans JH, Peto RE. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev. 2003;(2):CD002911. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD002911.</citation>
    <PMID>12804443</PMID>
  </reference>
  <reference>
    <citation>Bayne AP, Skoog SJ. Nocturnal enuresis: an approach to assessment and treatment. Pediatr Rev. 2014 Aug;35(8):327-34; quiz 335. doi: 10.1542/pir.35-8-327. Review.</citation>
    <PMID>25086164</PMID>
  </reference>
  <reference>
    <citation>Monda JM, Husmann DA. Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bed-wetting alarm systems. J Urol. 1995 Aug;154(2 Pt 2):745-8.</citation>
    <PMID>7609169</PMID>
  </reference>
  <reference>
    <citation>Ã–nol FF, Guzel R, Tahra A, Kaya C, Boylu U. Comparison of long-term efficacy of desmopressin lyophilisate and enuretic alarm for monosymptomatic enuresis and assessment of predictive factors for success: a randomized prospective trial. J Urol. 2015 Feb;193(2):655-61. doi: 10.1016/j.juro.2014.08.088. Epub 2014 Aug 23.</citation>
    <PMID>25158273</PMID>
  </reference>
  <reference>
    <citation>7.Rink A. Lully Sleep Guardian. In: Heinsimer K, editor. IU Health2016.</citation>
  </reference>
  <reference>
    <citation>8. Lully Sleep Guardian - Proven to Stop Night Terrors: Amazon; 2016 [cited 2015 2016]. Available from: http://www.amazon.com/Lully-Sleep-Guardian-Proven-Terrors/dp/B011LOUNCI/ref=sr_1_1?ie=UTF8&amp;qid=1457660065&amp;sr=8-1-spons&amp;keywords=lully+sleep+guardian&amp;psc=1#customerReviews.</citation>
  </reference>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>December 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Benjamin Whittam</investigator_full_name>
    <investigator_title>Assistant Professor of Urology</investigator_title>
  </responsible_party>
  <keyword>bedwetting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Nocturnal Enuresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
